• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

IDWeek 2024

October 16 – 19 , 2024

  1. Sipavibart (AZD3152)
  2. Evusheld (tixagevimab/cilgavimab)
  3. IVX-A12
  4. Flumist (Influenza Vaccine Live- Intranasal)
  5. Tozorakimab

PDF

A Need for Infection Prevention Among Patients With ESKD on Maintenance Dialysis: A First Step in Understanding How SARS-CoV-2 Impacts This Population

PDF

Individuals on Immunosuppressive or Immunomodulatory Therapies Remain at Increased Risk of COVID-19 Hospitalization, Despite Vaccination: Findings from INFORM, a Retrospective Health Database Study in England

PDF

COVID-19 Mortality Among Immunocompromised Individuals Is Consistently High Compared With Non-Immunocompromised Individuals: Results of the INFORM Study 2022, England

PDF

Safety and Pharmacokinetics of Long-acting SARS-Cov-2 Antibodies Tixagevimab/Cilgavimab (AZD7442) are Consistent After Repeat Dosing: Results From the PROVENT Substudy

PDF

Safety, Immunogenicity, and Pharmacokinetics of Repeat Dosing with AZD7442 (Tixagevimab/Cilgavimab): Final Analysis of the ENDURE Phase 2, Dose-Ranging Study in Immunocompromised Participants

PDF

Safety and Immunogenicity of a Respiratory Syncytial Virus and Human Metapneumovirus Virus-Like Particle Protein Subunit Combination Vaccine in 60 to 85-Year-Old Adults: Interim Results from a Phase 2a Clinical Trial

PDF

Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children: Data From the 2023/24 Influenza Season

PDF

Clinical Outcomes in Adults Hospitalized with Viral Lower Respiratory Tract Disease with a Bacterial and/or Fungal Coinfection: A US Claims Data Base Study

PDF

Temporal Patterns of Hospitalizations and Clinical Outcomes Associated with Viral Lower Respiratory Tract Disease in 2015-2023: A US Claims Analysis

Need Help?

Contact Us

Find an MSL

Chat with a Medical Affairs Associate

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Request a field medical follow-up

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice